

Resource Summary Report

Generated by [nidm-terms](#) on Sep 1, 2026

Agilent: Seahorse XFe96 Analyzer

RRID:SCR_019545

Type: Tool

Proper Citation

Agilent: Seahorse XFe96 Analyzer (RRID:SCR_019545)

Resource Information

URL: <https://www.agilent.com/cs/library/usermanuals/public/usermanual-xfe96-xf96-cell-characterization-cell-analysis-5994-0368en-agilent.pdf>

Proper Citation: Agilent: Seahorse XFe96 Analyzer (RRID:SCR_019545)

Description: Seahorse XFe96 Analyzer measures OCR and ECAR of live cells in 96 well plate format.

Synonyms: , Agilent Seahorse XFe96, Agilent Seahorse XFe96 Cell Analyzer

Resource Type: instrument resource

Keywords: Agilent, Seahorse XF Analyzer, Instrument Equipment, USEDit,

Resource Name: Agilent: Seahorse XFe96 Analyzer

Resource ID: SCR_019545

Alternate IDs: SCR_019538, Model_Number_Seahorse XFe96

Alternate URLs: <https://www.biocompare.com/10967-Cell-Analysis-Systems/12785609-Seahorse-XF-Pro-Analyzer/>

Old URLs: <https://www.agilent.com/en/products/cell-analysis/seahorse-analyzers/seahorse-xfe96-analyzer>

Record Creation Time: 20220129T080345+0000

Record Last Update: 20260829T182619+0000

Ratings and Alerts

No rating or validation information has been found for Agilent: Seahorse XFe96 Analyzer.

No alerts have been found for Agilent: Seahorse XFe96 Analyzer.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 53 mentions in open access literature.

Listed below are recent publications. The full list is available at [nidm-terms](#) .

Hue JJ, et al. (2026) Increased Glucose Availability Sensitizes Pancreatic Cancer to Macrophage-Targeting Immunotherapies. Cancer research communications, 6(6), 1470.

Lee S, et al. (2026) Functional characterization of SDHB variants clarifies hereditary pheochromocytoma and paraganglioma risk and genotype-phenotype relationships. The Journal of clinical investigation, 136(4).

Arumugam P, et al. (2026) Mitochondrial transfer to granulocytic myeloid-derived suppressor cells augments immunosuppressive activity. Cell reports, 45(3), 117057.

Grace E, et al. (2026) Metabolic plasticity and optimal redox homeostasis are essential for efficient metastatic colonization. Molecular metabolism, 109, 102382.

Huang KK, et al. (2026) Mutational Signatures and Clonal Hematopoiesis in Intestinal Metaplasia across Countries with Varying Stomach Cancer Incidence. Cancer discovery, 16(3), 497.

Amorim R, et al. (2026) Mitochondria-targeted antioxidant AntiOxBEN2 prevents metabolic dysfunction-associated steatotic liver disease (MASLD) by enhancing fatty acid oxidation and mitochondrial bioenergetics. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 196, 119022.

D'Addario SL, et al. (2026) Effects of neuromelanin buildup in rodent nigral dopamine neurons: implications for sex-biased vulnerability in Parkinson's disease. Neurobiology of disease, 223, 107378.

Wang Q, et al. (2026) Serglycin Drives LAG3+ Treg Differentiation and Immunosuppression in Gastric Cancer. Cancer research, 86(10), 2395.

Duan R, et al. (2026) Hepatocyte PLAGL2 deficiency alleviates MASH through MYD88-licensed inactivation of inflammasome. Cell reports, 45(2), 116942.

Gatti P, et al. (2026) Extracellular matrix signals promote actin-dependent mitochondrial elongation and activity. iScience, 29(3), 115171.

Rechtsteiner M, et al. (2026) Stage dependent alterations in PBMC mitochondrial bioenergetics in pediatric obesity: from insulin resistance to type 2 diabetes. Diabetes research and clinical practice, 237, 113300.

Berra C, et al. (2026) AhR-dependent ferroptosis as a therapeutic opportunity to counteract BRAFi-resistance in melanoma. *Cell death discovery*, 12(1).

Kelly B, et al. (2026) Sulfur partitioning from cysteine controls T cell proliferation and effector function. *Cell*, 189(12), 3669.

Turnquist A, et al. (2026) PI3K γ inhibition alters CD8 T cell differentiation and reprograms the tumor microenvironment following adoptive immunotherapy. *Journal of immunology* (Baltimore, Md. : 1950), 215(5).

Landi D, et al. (2025) A Checkpoint Reversal Receptor Mediates Bipartite Activation and Enhances CAR T-cell Function. *Cancer research communications*, 5(3), 527.

Arnone AA, et al. (2025) Endocrine-targeting therapies shift the breast microbiome to reduce estrogen receptor- α breast cancer risk. *Cell reports. Medicine*, 6(1), 101880.

Bischoff ME, et al. (2025) Copper Drives Remodeling of Metabolic State and Progression of Clear Cell Renal Cell Carcinoma. *Cancer discovery*, 15(2), 401.

Lin J, et al. (2025) Nudix Hydrolase 13 Impairs the Initiation of Colorectal Cancer by Inhibiting PKM1 ADP-Ribosylation. *Advanced science* (Weinheim, Baden-Wurttemberg, Germany), 12(13), e2410058.

Gamma JM, et al. (2025) Zelenirstat Inhibits N-Myristoyltransferases to Disrupt Src Family Kinase Signaling and Oxidative Phosphorylation, Killing Acute Myeloid Leukemia Cells. *Molecular cancer therapeutics*, 24(1), 69.

Ali MM, et al. (2025) Mechanisms of mitochondrial reactive oxygen species action in bone mesenchymal cells. *The Journal of biological chemistry*, 301(9), 110551.